Headlines
-
HPV vax and screening decline
Tuesday | Nov 25 2025FALLING HPV vaccination and cervical screening rates are putting elimination of cervical cancer in Australia at risk, according to the latest annual report by the NHMRC Centre of Research Excellence in Cervical Cancer Control.
-
T2D drug helps with type 1 diabetes
Tuesday | Nov 25 2025RESEARCHERS at the Garvan Institute have discovered that metformin, a drug typically used in type 2 diabetes, reduces insulin needs in type 1 diabetes, opening the door for improved management of the condition.
-
Market sentiment positive
Monday | Nov 24 2025DEMAND is strong for pharmacists looking to buy pharmacies, according to the most recent results of the Attain Pharmacy Market Sentiment Survey, with data also suggesting that future supply is likely to increase in the next few years.
-
Is that the right vaccine?
Monday | Nov 24 2025PHARMACEUTICAL Defence Limited (PDL) is reminding pharmacists about the importance of covering off key checkpoints before administering a vaccine to ensure the correct one is provided.
-
-
Cooper’s legacy honoured
Friday | Nov 21 2025PHARMACY peak bodies came together alongside the University of Canberra Pharmacy School to host the inaugural Professor Gabrielle Cooper OAM Address in Canberra last night.
-
ABS finds health access improving
Friday | Nov 21 2025FEWER Australians are delaying or not using selected health services when needed compared to two years ago, according to new data released this week by the Australian Bureau of Statistics (ABS).
-
Guild Tassie winners named
Thursday | Nov 20 2025THE Pharmacy Guild of Australia Tasmania Branch celebrated outstanding contributors to community pharmacy at the 2026 Tasmania Community Pharmacy Awards, held in Hobart last night.
-
A way to go with med cannabis
Thursday | Nov 20 2025AUSTRALIAN consumers are increasingly embracing contemporary healthcare, including telehealth and medicinal cannabis, according to research commissioned by Montu healthcare group.
-
mRNA flu vax promise
Thursday | Nov 20 2025A NEW mRNA-based flu vaccine developed by Pfizer has been found to be 34.5% more effective against influenza-like illness compared to current flu vaccines, according to a new trial published in the New England Journal of Medicine.
